Assay Ref. Price ( $ )
non-peptide receptors
Adenosine
binding A1 (antagonist radioligand) Human 0002
61 /well
cellular new protocol A1 Human G127 no discount
63 /well
for both effects (1 conc., n=1)
cellular A1 (inverse agonist effect) Human 2408
178 /well
min 16 wells specific discount
tisssue A1 0294
2103 /cpd
specific discount
binding A2A (agonist radioligand) Human 0004
61 /well
cellular A2A G002 no discount
63 /well
for both effects (1 conc., n=1)
cellular A2A (inverse agonist effect) Human 2409
178 /well
min 16 wells specific discount
tisssue A2A 0295
1461 /cpd
specific discount
binding new protocol A2B (antagonist radioligand) Human 0005
61 /well
tisssue A2B 0783
1461 /cpd
specific discount
cellular new protocol A3 Human G107 no discount
63 /well
for both effects (1 conc., n=1)
binding A3 (agonist radioligand) Human 0006
61 /well
Adrenergic
binding alpha1 (non-selective) (antagonist radioligand) 0008
29 /well
tisssue alpha1 (non-selective) 0296
1284 /cpd
specific discount
binding alpha1A (antagonist radioligand) Human 2338
61 /well
binding alpha1A (antagonist radioligand) 0009
70 /well
cellular alpha 1A Human G004 no discount
63 /well
for both effects (1 conc., n=1)
binding alpha1B (antagonist radioligand) Human 1633
61 /well
cellular alpha 1B Human G005 no discount
63 /well
for both effects (1 conc., n=1)
binding alpha1D (antagonist radioligand) Human 1942
61 /well
binding alpha2 (non-selective) (antagonist radioligand) 0011
29 /well
tisssue alpha2 (non-selective) 0297
1461 /cpd
specific discount
cellular new protocol alpha 2C Human G006 no discount
63 /well
for both effects (1 conc., n=1)
cellular beta 1 Human G007 no discount
63 /well
for both effects (1 conc., n=1)
cellular beta1 (inverse agonist effect) Human 2377
178 /well
min 16 wells specific discount
tisssue beta1 0298
2103 /cpd
specific discount
tisssue beta2 0299
1461 /cpd
specific discount
binding beta1 (agonist radioligand) Human 0018
61 /well
binding beta3 (antagonist radioligand) Human 0227
61 /well
cellular beta 3 Human G009 no discount
63 /well
for both effects (1 conc., n=1)
binding beta2 (agonist radioligand) Human 0020
61 /well
tisssue beta3 0300
1284 /cpd
specific discount
Benzodiazepine
binding BZD (peripheral) (antagonist radioligand) 0029
29 /well
Cannabinoid
binding CB1 (agonist radioligand) Human 0036
61 /well
cellular new protocol CB1 Human G012 no discount
63 /well
for both effects (1 conc., n=1)
tisssue CB1 0307
2103 /cpd
specific discount
cellular CB1 (inverse agonist effect) Human 2378
178 /well
min 16 wells specific discount
Dopamine
binding new protocol D1 (antagonist radioligand) Human 0044
61 /well
cellular D1 Human G014 no discount
63 /well
for both effects (1 conc., n=1)
tisssue D1 0309
2103 /cpd
specific discount
binding new protocol D2S (antagonist radioligand) Human 0046
61 /well
binding D2S (agonist radioligand) Human 1322
61 /well
cellular new protocol D2S Human G116 no discount
63 /well
for both effects (1 conc., n=1)
binding D2L (antagonist radioligand) Human 1405
61 /well
tisssue D2 0310
1284 /cpd
specific discount
cellular new protocol D3 Human G016 no discount
63 /well
for both effects (1 conc., n=1)
cellular new protocol D4.4 Human G017 no discount
63 /well
for both effects (1 conc., n=1)
Histamine
binding H1 (antagonist radioligand) 0077
70 /well
cellular H1 Human G115 no discount
63 /well
for both effects (1 conc., n=1)
tisssue H1 0316
1284 /cpd
specific discount
binding H2 (antagonist radioligand) Human 1208
61 /well
binding new protocol H2 (antagonist radioligand) 0079
108 /well
min 16 wells specific discount
cellular H2 (inverse agonist effect) Human 2380
178 /well
min 16 wells specific discount
tisssue H2 0317
2103 /cpd
specific discount
binding H3 (agonist radioligand) Human 1332
61 /well
binding H3 (agonist radioligand) 0080
70 /well
Imidazoline
binding I2 (antagonist radioligand) 0081
40 /well
Melatonin
binding MT1 (ML1A) (agonist radioligand) Human 1538
61 /well
cellular new protocol MT1 (ML1A) Human G136 no discount
63 /well
for both effects (1 conc., n=1)
Muscarinic
binding new protocol M (non-selective) (antagonist radioligand) 0089
29 /well
binding M1 (antagonist radioligand) Human 0091
61 /well
cellular M1 Human G029 no discount
63 /well
for both effects (1 conc., n=1)
tisssue M1 0318
1284 /cpd
specific discount
binding M2 (antagonist radioligand) Human 0093
61 /well
binding M2 (agonist radioligand) Human 1626
61 /well
cellular new protocol M2 Human G030 no discount
63 /well
for both effects (1 conc., n=1)
cellular M2 (inverse agonist effect) Human 2411
178 /well
min 16 wells specific discount
tisssue M2 0319
2103 /cpd
specific discount
binding M3 (antagonist radioligand) Human 0095
61 /well
tisssue M3 0320
1461 /cpd
specific discount
Platelet activating factor
binding PAF (agonist radioligand) Human 0915
70 /well
cellular PAF Human G034 no discount
63 /well
for both effects (1 conc., n=1)
binding PAF (agonist radioligand) - custom offer 0123
inquire
specific discount
Prostanoid
binding IP (PGI2) (agonist radioligand) Human 2230
70 /well
cellular IP (PGI2) Human G039 no discount
63 /well
for both effects (1 conc., n=1)
binding TP (TXA2/PGH2) (antagonist radioligand) Human 2048
61 /well
cellular TP (TXA2/PGH2) Human G040 no discount
63 /well
for both effects (1 conc., n=1)
Purinergic
binding P2Y (agonist radioligand) 0128
40 /well
cellular P2Y1 Human G041 no discount
63 /well
for both effects (1 conc., n=1)
cellular P2Y2 Human G108 no discount
63 /well
for both effects (1 conc., n=1)
cellular P2Y4 Human G042 no discount
63 /well
for both effects (1 conc., n=1)
cellular P2Y6 Human G043 no discount
63 /well
for both effects (1 conc., n=1)
Serotonin
binding 5-HT (non-selective) (agonist radioligand) 0129
40 /well
binding 5-HT1B (antagonist radioligand) 0132
40 /well
cellular new protocol 5-HT1B G126 no discount
63 /well
for both effects (1 conc., n=1)
binding 5-HT1D (agonist radioligand) 1974
61 /well
cellular new protocol 5-HT1D G112 no discount
63 /well
for both effects (1 conc., n=1)
binding 5-HT2A (antagonist radioligand) Human 0135
61 /well
binding 5-HT2A (agonist radioligand) Human 0471
61 /well
cellular new assay 5-HT2A Human G181
63 /well
for both effects (1 conc., n=1)
tisssue 5-HT2A 0334
1284 /cpd
specific discount
binding 5-HT2B (antagonist radioligand) Human 1609
61 /well
binding 5-HT2B (agonist radioligand) Human 1333
61 /well
tisssue 5-HT2B 0333
1461 /cpd
specific discount
binding 5-HT4e (antagonist radioligand) Human 0501
61 /well
tisssue 5-HT4 0336
1461 /cpd
specific discount
binding new protocol 5-HT7 (agonist radioligand) Human 0144
61 /well
cellular new protocol 5-HT7 Human G051 no discount
63 /well
for both effects (1 conc., n=1)
peptide receptors
Angiotensin-II
binding AT1 (antagonist radioligand) Human 0024
61 /well
tisssue AT1 0301
1284 /cpd
specific discount
cellular AT1 Human G052 no discount
63 /well
for both effects (1 conc., n=1)
binding AT2 (agonist radioligand) Human 0026
61 /well
Apelin
binding new protocol APJ (apelin) (agonist radioligand) Human 2154
70 /well
cellular new protocol APJ (apelin) Human G146 no discount
63 /well
for both effects (1 conc., n=1)
Atrial natriuretic peptide
binding ANP (agonist radioligand) 0027
108 /well
min 16 wells specific discount
Bradykinin
tisssue B1 Human 0935
2103 /cpd
specific discount
tisssue B1 0304
1284 /cpd
specific discount
binding B2 (agonist radioligand) Human 0033
61 /well
cellular B2 Human G056 no discount
63 /well
for both effects (1 conc., n=1)
tisssue B2 Human 0623
2103 /cpd
specific discount
Calcitonin gene-related peptide
binding CGRP (agonist radioligand) Human 0373
70 /well
cellular new protocol CGRP Human G058 no discount
63 /well
for both effects (1 conc., n=1)
tisssue CGRP 0306
2103 /cpd
specific discount
Endothelin
binding ETA (agonist radioligand) Human 0054
61 /well
cellular ETA Human G067 no discount
63 /well
for both effects (1 conc., n=1)
tisssue ETA 0311
2103 /cpd
specific discount
binding ETB (agonist radioligand) Human 0056
61 /well
cellular ETB Human G068 no discount
63 /well
for both effects (1 conc., n=1)
tisssue ETB 0312
2103 /cpd
specific discount
Growth factors
binding EGF (agonist radioligand) Human 0069
64 /well
min 16 wells specific discount
binding VEGF (agonist radioligand) - custom offer Human 0672
inquire
specific discount
Neurokinin
binding NK1 (agonist radioligand) Human 0100
61 /well
cellular NK1 Human G085 no discount
63 /well
for both effects (1 conc., n=1)
tisssue NK1 0624
1461 /cpd
specific discount
binding NK2 (agonist radioligand) Human 0102
61 /well
cellular NK2 Human G086 no discount
63 /well
for both effects (1 conc., n=1)
tisssue NK2 0322
1461 /cpd
specific discount
binding NK3 (antagonist radioligand) Human 0104
61 /well
binding NK3 (agonist radioligand) Human 1240
61 /well
cellular NK3 Human G087 no discount
63 /well
for both effects (1 conc., n=1)
tisssue NK3 0625
1461 /cpd
specific discount
Neuropeptide Y
binding Y (non-selective) (agonist radioligand) 0105
48 /well
binding Y1 (agonist radioligand) Human 0106
61 /well
cellular new protocol Y1 Human G088 no discount
63 /well
for both effects (1 conc., n=1)
tisssue Y1 0324
1284 /cpd
specific discount
Neurotensin
binding NT (non-selective) (agonist radioligand) 0465
64 /well
min 16 wells specific discount
tisssue NT (non-selective) 0327
1461 /cpd
specific discount
binding NTS1 (NT1) (agonist radioligand) Human 0109
61 /well
cellular NTS1 (NT1) Human G089 no discount
63 /well
for both effects (1 conc., n=1)
Relaxin
binding RXFP1 (agonist radioligand) Human 2058
61 /well
cellular RXFP1 Human G094 no discount
63 /well
for both effects (1 conc., n=1)
Urotensin-II
binding UT (agonist radioligand) Human 1386
61 /well
cellular UT Human G099 no discount
63 /well
for both effects (1 conc., n=1)
Vasoactive intestinal peptide
binding new protocol VPAC2 (VIP2) (agonist radioligand) Human 0487
70 /well
cellular VPAC2 (VIP2) Human G102 no discount
63 /well
for both effects (1 conc., n=1)
tisssue VPAC2 (VIP2) 0622
1461 /cpd
specific discount
Vasopressin
binding V1a (agonist radioligand) Human 0159
61 /well
cellular V1a Human G104 no discount
63 /well
for both effects (1 conc., n=1)
tisssue V1a 0338
1284 /cpd
specific discount
nuclear receptors
Non-steroid nuclear receptors
binding PPARalpha (agonist radioligand) Human 0640
110 /well
cellular new protocol PPARalpha Human G131 no discount
63 /well
for both effects (1 conc., n=1)
cellular PPARgamma Human G124 no discount
63 /well
for both effects (1 conc., n=1)
binding new protocol PPARgamma (agonist radioligand) Human 0641
70 /well
ion channels
Intracellular ligand-gated channels      Ca2+ channels
binding IP3 (agonist radioligand) 0083
108 /well
min 16 wells specific discount
Voltage-gated channels
binding L (dihydropyridine site) (antagonist radioligand) 0161
40 /well
binding L (diltiazem site) (benzothiazepines) (antagonist radioligand) 0162
40 /well
binding new protocol L (verapamil site) (phenylalkylamine) (antagonist radioligand) 0163
40 /well
tisssue L 0339
1284 /cpd
specific discount
Voltage-gated channels      K+ channels
binding hERG (membrane preparation) (antagonist radioligand) Human 1868
70 /well
hERG (automated patch-clamp) Human 2245 no discount
370 /cpd
hERG (conventional patch-clamp) Human 2027 no discount
925 /cpd
binding KATP (antagonist radioligand) 0165
61 /well
tisssue KATP 0340
1284 /cpd
specific discount
binding new protocol KV (antagonist radioligand) 0166
40 /well
binding SKCa (antagonist radioligand) 0167
48 /well
Voltage-gated channels      Na+ channels
binding site 2 (antagonist radioligand) 0169
40 /well
amine transporters
Adenosine
binding adenosine transporter (antagonist radioligand) 0007
110 /well
Norepinephrine
binding norepinephrine transporter (antagonist radioligand) Human 0355
61 /well
Kinases
Protein-tyrosine kinases      RTK
cellular VEGFR kinase (stimulant effect) Human 2696 no discount
26 /well
cellular VEGFR kinase Human G142 no discount
44 /cpd
for both effects (1 conc., n=1)
cellular VEGFR kinase (inhibitor effect) Human 2697 no discount
26 /well
Protein-serine/threonine kinases      CMGC
ERK5 (MAPK7) Human 2680 no discount
13 /well
GSK3alpha Human 2842 no discount
13 /well
Protein-serine/threonine kinases      CaMK
PKD2 Human 1729
19 /well
new protocol PKD3 Human 1982
19 /well
Protein-serine/threonine kinases      AGC
GRK3 /BARK2 (ADRBK2) Human 2627
19 /well
new protocol PKG1beta Human 1730
19 /well
assay converted from HTRF to LANCEUltra SGK1 Human 2929 no discount
13 /well
Non-kinase enzymes
Phosphodiesterases
PDE1B Human 2431
61 /well
PDE2A1 Human 2426
61 /well
PDE3A Human 2432
61 /well
PDE4D2 Human 2434
61 /well
PDE7A Human 2351
61 /well
Second messenger systems      Inositol phosphate
binding IP3 (agonist radioligand) 0083
108 /well
min 16 wells specific discount
Proteases      Metalloproteases
ACE Human 0979
110 /well
tisssue ACE 0302
1284 /cpd
specific discount
ACE-2 Human 1954
110 /well
ECE-1 Human 0184
110 /well
tisssue ECE-1 0313
2103 /cpd
specific discount
neutral endopeptidase Human 0509
110 /well
Toxicity
cardiac toxicity      K+ channel      hERG
binding hERG (membrane preparation) (antagonist radioligand) Human 1868
70 /well
hERG (automated patch-clamp) Human 2245 no discount
370 /cpd
hERG (conventional patch-clamp) Human 2027 no discount
925 /cpd